Anacin
- Product NDC
- 63736-200
- 11-digit product format
- 637360200
- Labeler code
- 63736
- Product ID
- 63736-200_4895609d-1ec8-4ebd-8b6e-61ccd452ad5b
- Type
- HUMAN OTC DRUG
- Nonproprietary name
- Asprin and Caffeine
- Dosage form
- TABLET
- Route
- ORAL
- Labeler
- Insight Pharmaceuticals LLC
- Application
- M013
- Marketing category
- OTC MONOGRAPH DRUG
- Marketing start
- 2009-06-25
- Substance
- ASPIRIN; CAFFEINE
- Active strength
- 400; 32 mg/1; mg/1
- Pharmacologic classes
- Anti-Inflammatory Agents, Non-Steroidal [CS], Central Nervous System Stimulant [EPC], Central Nervous System Stimulation [PE], Cyclooxygenase Inhibitors [MoA], Decreased Platelet Aggregation [PE], Decreased Prostaglandin Production [PE], Methylxanthine [EPC], Nonsteroidal Anti-inflammatory Drug [EPC], Platelet Aggregation Inhibitor [EPC], Xanthines [CS]
- NDC exclude flag
- No
- Listing certified through
- 2027-12-31
- Current FDA listing
- Yes
NDC auxiliary status#
These records are reproduced from FDA’s unfinished, excluded, and compounder listings. They describe what appeared in the source files; a missing record does not establish a regulatory status. View all current auxiliary records, including entries without an NDC. · View the auxiliary file history.
| Dataset | Scope | Product NDC | Package NDC | Code | Status | Reporting period | Source date |
|---|---|---|---|---|---|---|---|
| excluded package | package | 63736-200 | 63736-200-04 | D | Discontinued by firm | 2026-10-16 | |
| excluded package | package | 63736-200 | 63736-200-30 | D | Discontinued by firm | 2026-10-16 | |
| excluded package | package | 63736-200 | 63736-200-50 | D | Discontinued by firm | 2026-10-16 | |
| excluded package | package | 63736-200 | 63736-200-91 | D | Discontinued by firm | 2026-10-16 | |
| excluded package | package | 63736-200 | 63736-200-92 | D | Discontinued by firm | 2026-10-16 | |
| excluded package | package | 63736-200 | 63736-200-95 | D | Discontinued by firm | 2026-10-16 |
Observed NDC auxiliary status history#
This history shows the information present in each captured FDA auxiliary file. It is not a continuous regulatory timeline, and a missing record does not establish a status.
| Captured / source date | Package NDC | Snapshot | Source SHA-256 |
|---|---|---|---|
| 2025-12-14 17:58 UTC · source 2025-12-05 | 63736-200-04 | d630ba8d3edf… | 732f749b63fb… |
| 2025-12-14 17:58 UTC · source 2025-12-05 | 63736-200-30 | d630ba8d3edf… | 732f749b63fb… |
| 2025-12-14 17:58 UTC · source 2025-12-05 | 63736-200-92 | d630ba8d3edf… | 732f749b63fb… |
| 2025-12-14 17:58 UTC · source 2025-12-05 | 63736-200-50 | d630ba8d3edf… | 732f749b63fb… |
| 2025-12-14 17:58 UTC · source 2025-12-05 | 63736-200-95 | d630ba8d3edf… | 732f749b63fb… |
| 2025-12-14 17:58 UTC · source 2025-12-05 | 63736-200-91 | d630ba8d3edf… | 732f749b63fb… |
| 2025-08-27 00:01 UTC · source 2025-08-26 | 63736-200-50 | f5e01cc5f278… | a2eaf40c39c3… |
| 2025-08-27 00:01 UTC · source 2025-08-26 | 63736-200-92 | f5e01cc5f278… | a2eaf40c39c3… |
| 2025-08-27 00:01 UTC · source 2025-08-26 | 63736-200-04 | f5e01cc5f278… | a2eaf40c39c3… |
| 2025-08-27 00:01 UTC · source 2025-08-26 | 63736-200-30 | f5e01cc5f278… | a2eaf40c39c3… |
| 2025-08-27 00:01 UTC · source 2025-08-26 | 63736-200-91 | f5e01cc5f278… | a2eaf40c39c3… |
| 2025-08-27 00:01 UTC · source 2025-08-26 | 63736-200-95 | f5e01cc5f278… | a2eaf40c39c3… |
| 2025-04-01 02:39 UTC · source 2025-03-31 | 63736-200-50 | 2ef7874e63bc… | 57b86245f4fa… |
| 2025-04-01 02:39 UTC · source 2025-03-31 | 63736-200-92 | 2ef7874e63bc… | 57b86245f4fa… |
| 2025-04-01 02:39 UTC · source 2025-03-31 | 63736-200-04 | 2ef7874e63bc… | 57b86245f4fa… |
| 2025-04-01 02:39 UTC · source 2025-03-31 | 63736-200-30 | 2ef7874e63bc… | 57b86245f4fa… |
| 2025-04-01 02:39 UTC · source 2025-03-31 | 63736-200-91 | 2ef7874e63bc… | 57b86245f4fa… |
| 2025-04-01 02:39 UTC · source 2025-03-31 | 63736-200-95 | 2ef7874e63bc… | 57b86245f4fa… |
| 2025-03-28 20:22 UTC · source 2025-03-28 | 63736-200-50 | a1b67e2a42f9… | c4cf2c586c0d… |
| 2025-03-28 20:22 UTC · source 2025-03-28 | 63736-200-92 | a1b67e2a42f9… | c4cf2c586c0d… |
| 2025-03-28 20:22 UTC · source 2025-03-28 | 63736-200-04 | a1b67e2a42f9… | c4cf2c586c0d… |
| 2025-03-28 20:22 UTC · source 2025-03-28 | 63736-200-30 | a1b67e2a42f9… | c4cf2c586c0d… |
| 2025-03-28 20:22 UTC · source 2025-03-28 | 63736-200-91 | a1b67e2a42f9… | c4cf2c586c0d… |
| 2025-03-28 20:22 UTC · source 2025-03-28 | 63736-200-95 | a1b67e2a42f9… | c4cf2c586c0d… |
| 2025-03-22 03:12 UTC · source 2025-03-21 | 63736-200-50 | cfe11265f3b6… | 090c488252e2… |
| 2025-03-22 03:12 UTC · source 2025-03-21 | 63736-200-92 | cfe11265f3b6… | 090c488252e2… |
| 2025-03-22 03:12 UTC · source 2025-03-21 | 63736-200-04 | cfe11265f3b6… | 090c488252e2… |
| 2025-03-22 03:12 UTC · source 2025-03-21 | 63736-200-30 | cfe11265f3b6… | 090c488252e2… |
| 2025-03-22 03:12 UTC · source 2025-03-21 | 63736-200-91 | cfe11265f3b6… | 090c488252e2… |
| 2025-03-22 03:12 UTC · source 2025-03-21 | 63736-200-95 | cfe11265f3b6… | 090c488252e2… |
| 2025-03-10 12:48 UTC · source 2025-03-10 | 63736-200-50 | cdf11ea48f46… | ba0047e9e063… |
| 2025-03-10 12:48 UTC · source 2025-03-10 | 63736-200-92 | cdf11ea48f46… | ba0047e9e063… |
| 2025-03-10 12:48 UTC · source 2025-03-10 | 63736-200-04 | cdf11ea48f46… | ba0047e9e063… |
| 2025-03-10 12:48 UTC · source 2025-03-10 | 63736-200-30 | cdf11ea48f46… | ba0047e9e063… |
| 2025-03-10 12:48 UTC · source 2025-03-10 | 63736-200-91 | cdf11ea48f46… | ba0047e9e063… |
| 2025-03-10 12:48 UTC · source 2025-03-10 | 63736-200-95 | cdf11ea48f46… | ba0047e9e063… |
| 2025-02-02 03:52 UTC · source 2025-01-31 | 63736-200-50 | 302b2466d912… | e7b80fea0513… |
| 2025-02-02 03:52 UTC · source 2025-01-31 | 63736-200-92 | 302b2466d912… | e7b80fea0513… |
| 2025-02-02 03:52 UTC · source 2025-01-31 | 63736-200-04 | 302b2466d912… | e7b80fea0513… |
| 2025-02-02 03:52 UTC · source 2025-01-31 | 63736-200-30 | 302b2466d912… | e7b80fea0513… |
| 2025-02-02 03:52 UTC · source 2025-01-31 | 63736-200-91 | 302b2466d912… | e7b80fea0513… |
| 2025-02-02 03:52 UTC · source 2025-01-31 | 63736-200-95 | 302b2466d912… | e7b80fea0513… |
| 2025-01-20 13:05 UTC · source 2025-01-20 | 63736-200-50 | ed331223b511… | 672a5bd82f5f… |
| 2025-01-20 13:05 UTC · source 2025-01-20 | 63736-200-92 | ed331223b511… | 672a5bd82f5f… |
| 2025-01-20 13:05 UTC · source 2025-01-20 | 63736-200-04 | ed331223b511… | 672a5bd82f5f… |
| 2025-01-20 13:05 UTC · source 2025-01-20 | 63736-200-30 | ed331223b511… | 672a5bd82f5f… |
| 2025-01-20 13:05 UTC · source 2025-01-20 | 63736-200-91 | ed331223b511… | 672a5bd82f5f… |
| 2025-01-20 13:05 UTC · source 2025-01-20 | 63736-200-95 | ed331223b511… | 672a5bd82f5f… |
| 2025-01-11 03:41 UTC · source 2025-01-10 | 63736-200-04 | 0efc9e666f02… | f202fb6c5f17… |
| 2025-01-11 03:41 UTC · source 2025-01-10 | 63736-200-91 | 0efc9e666f02… | f202fb6c5f17… |
| 2025-01-11 03:41 UTC · source 2025-01-10 | 63736-200-95 | 0efc9e666f02… | f202fb6c5f17… |
| 2025-01-11 03:41 UTC · source 2025-01-10 | 63736-200-30 | 0efc9e666f02… | f202fb6c5f17… |
| 2024-11-09 02:27 UTC · source 2024-11-08 | 63736-200-04 | ad56d346431e… | cc804d4bbf1e… |
| 2024-11-09 02:27 UTC · source 2024-11-08 | 63736-200-91 | ad56d346431e… | cc804d4bbf1e… |
| 2024-11-09 02:27 UTC · source 2024-11-08 | 63736-200-95 | ad56d346431e… | cc804d4bbf1e… |
| 2024-11-09 02:27 UTC · source 2024-11-08 | 63736-200-30 | ad56d346431e… | cc804d4bbf1e… |
| 2024-10-04 04:10 UTC · source 2024-10-03 | 63736-200-91 | 367a005e9d99… | 383a685ebd0f… |
| 2024-10-04 04:10 UTC · source 2024-10-03 | 63736-200-04 | 367a005e9d99… | 383a685ebd0f… |
| 2024-10-04 04:10 UTC · source 2024-10-03 | 63736-200-30 | 367a005e9d99… | 383a685ebd0f… |
| 2024-10-04 04:10 UTC · source 2024-10-03 | 63736-200-95 | 367a005e9d99… | 383a685ebd0f… |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
Additional Listing Data#
- Finished product
- Yes
- Brand name base
- Anacin
- Listing expiration
- 2027-12-31
Active Ingredients#
| Ingredient | Strength |
|---|---|
| ASPIRIN | 400 mg/1 |
| CAFFEINE | 32 mg/1 |
Harmonized UNII identifiers#
| Identifier | FDA.report destination |
|---|---|
| R16CO5Y76E | Internal UNII lookup |
| 3G6A5W338E | Internal UNII lookup |
Harmonized RxCUI identifiers#
Harmonized SPL set identifiers#
| Identifier | FDA.report destination |
|---|---|
| 51ab0ee3-3c94-424d-a30a-2d6c14e3d8ff | Available on FDA.report |
DailyMed Product Concepts#
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 63736-200-04 | Anacin | 1 in 1 BOX | TABLET | 1 | 9 | |
| 63736-200-04 | Anacin | 4 in 1 BLISTER PACK | TABLET | 4 | 9 | |
| 63736-200-30 | Anacin | 1 in 1 BOX | TABLET | 1 | 9 | |
| 63736-200-30 | Anacin | 30 in 1 BOTTLE | TABLET | 30 | 9 | |
| 63736-200-50 | Anacin | 1 in 1 BOX | TABLET | 1 | 9 | |
| 63736-200-50 | Anacin | 50 in 1 BOTTLE | TABLET | 50 | 9 | |
| 63736-200-90 | Anacin | 100 in 1 BOTTLE | TABLET | 100 | 9 | |
| 63736-200-90 | Anacin | 1 in 1 BOX | TABLET | 1 | 9 | |
| 63736-200-91 | Anacin | 1 in 1 BOX | TABLET | 1 | 9 | |
| 63736-200-91 | Anacin | 130 in 1 BOTTLE | TABLET | 130 | 9 | |
| 63736-200-92 | Anacin | 125 in 1 BOX | TABLET | 125 | 9 | |
| 63736-200-92 | Anacin | 1 in 1 POUCH | TABLET | 1 | 9 | |
| 63736-200-93 | Anacin | 300 in 1 BOTTLE | TABLET | 300 | 9 | |
| 63736-200-93 | Anacin | 1 in 1 BOX | TABLET | 1 | 9 | |
| 63736-200-95 | Anacin | 750 in 1 BOX | TABLET | 750 | 9 | |
| 63736-200-95 | Anacin | 1 in 1 POUCH | TABLET | 1 | 9 |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | DailyMed label | SPL version | Uploaded |
|---|---|---|---|---|---|
| Aspirin | ACTIVE INGREDIENT | R16CO5Y76E | ANACIN (ASPRIN AND CAFFEINE) TABLET [INSIGHT PHARMACEUTICALS] | 2 | |
| Caffeine | ACTIVE INGREDIENT | 3G6A5W338E | ANACIN (ASPRIN AND CAFFEINE) TABLET [INSIGHT PHARMACEUTICALS] | 2 | |
| Aspirin | ACTIVE MOIETY | R16CO5Y76E | ANACIN (ASPRIN AND CAFFEINE) TABLET [INSIGHT PHARMACEUTICALS] | 2 | |
| Caffeine | ACTIVE MOIETY | 3G6A5W338E | ANACIN (ASPRIN AND CAFFEINE) TABLET [INSIGHT PHARMACEUTICALS] | 2 | |
| cellulose, microcrystalline | INACTIVE INGREDIENT | OP1R32D61U | ANACIN (ASPRIN AND CAFFEINE) TABLET [INSIGHT PHARMACEUTICALS] | 2 | |
| hypromelloses | INACTIVE INGREDIENT | 3NXW29V3WO | ANACIN (ASPRIN AND CAFFEINE) TABLET [INSIGHT PHARMACEUTICALS] | 2 | |
| sodium lauryl sulfate | INACTIVE INGREDIENT | 368GB5141J | ANACIN (ASPRIN AND CAFFEINE) TABLET [INSIGHT PHARMACEUTICALS] | 2 |
DailyMed Dashboard NDC Coverage#
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Aspirin 81 mg Low Dose | ASPIRIN | CVS WOONSOCKET PRESCRIPTION CENTER, INCORPORATED | 23b29044-6389-42ea-839a-5351557a6ce3 | 2026-04-23 | Warnings | M013 |
| Childrens Pain and Fever | ACETAMINOPHEN | CVS WOONSOCKET PRESCRIPTION CENTER, INCORPORATED | 4a70867e-481d-4f01-9da3-d85663a1672e | 2026-04-23 | Warnings | M013 |
| Aspirin Low Dose | ASPIRIN | United Natural Foods, Inc. dba UNFI | 07edcb31-d31d-4607-98c3-dcb1e062cc70 | 2026-04-22 | Warnings | M013 |
| Acetaminophen | ACETAMINOPHEN | Cardinal Health 107, LLC | ee50c5ee-1a61-4efc-aca9-42d897d6a3b8 | 2026-04-22 | Warnings | M013 |
| Aspirin | ASPIRIN | CVS PHARMACY | 904a2b21-d911-40c3-9e4b-59543ea5be4f | 2026-04-22 | Warnings | M013 |
| Pamprin Multi-Symptom Maximum Strength | ACETAMINOPHEN, PAMABROM, PYRILAMINE MALEATE | Focus Consumer Healthcare, LLC | 60b3286d-5698-df50-e053-2991aa0afbe2 | 2026-04-20 | Warnings | M013 |
| Acetaminophen Extra Strength | ACETAMINOPHEN | CVS PHARMACY | af6fe4a9-2d18-4fed-b952-0a7866f65251 | 2026-04-20 | Warnings | M013 |
| Aspirin 81 mg | ASPIRIN | Preferred Pharmaceuticals Inc. | ac7f11d2-cbfd-4610-a652-fc2f1ea41d7e | 2026-04-20 | Warnings | M013 |
| Parry-500mg Acetaminophen | ACETAMINOPHEN | MDC PHARMACEUTICALS LIMITED | fb07ba10-3210-41bc-9310-c952118fdcf3 | 2026-04-17 | Warnings | M013 |
| Aspirin NSAID | ASPIRIN | Valu Merchandisers Company | 0cc46a81-54c9-44b7-b384-79d25255eff2 | 2026-04-17 | Warnings | M013 |
| Headache Relief Extra Strength | ACETAMINOPHEN, ASPIRIN AND CAFFEINE | Valu Merchandisers Company | 99de2c41-59b0-42e7-847e-e51229c6164f | 2026-04-17 | Warnings | M013 |
| Pain and Fever Childrens | ACETAMINOPHEN | Walgreen Company | 1f3e2895-5ef7-4e6a-8d2e-b805d148f980 | 2026-04-16 | Warnings | M013 |
| Childrens TYLENOL | ACETAMINOPHEN | Kenvue Brands LLC | b297aff8-a08b-4d37-b168-800a56564cbd | 2026-04-16 | Warnings | M013 |
| Childrens Tylenol | ACETAMINOPHEN | Kenvue Brands LLC | 9782fe86-d72a-4231-b1ba-d3f3b4ee49e3 | 2026-04-16 | Warnings | M013 |
| Pain Relief PM Extra Strength | ACETAMINOPHEN AND DIPHENHYDRAMINE HCL | DOLGENCORP, LLC | 8e65478b-7a7b-416c-b8e3-23dad79f8cc1 | 2026-04-16 | Warnings | M013 |
| Aspirin Low Dose | ASPIRIN | Valu Merchandisers Company | c9e384e5-fa9b-4c75-b5e3-16eb8db662ef | 2026-04-16 | Warnings | M013 |
| Acetaminophen | ACETAMINOPHEN | Preferred Pharmaceuticals Inc. | b6abfbbb-9826-4cd6-940f-3a314480a5a5 | 2026-04-15 | Warnings | M013 |
| Good Sense Pain and Fever | ACETAMINOPHEN | L. Perrigo Company | f7137fe6-582e-43a4-8302-90ca54cd1de3 | 2026-04-14 | Warnings | M013 |
| Acetaminophen | ACETAMINOPHEN | Cardinal Health 107, LLC | e13656eb-513e-411e-bdae-35ff1ba7cfc1 | 2026-04-13 | Warnings | M013 |
| CareOne Acetaminophen | ACETAMINOPHEN | American Sales Company | b4f54465-3232-4685-9570-90be00876577 | 2026-04-12 | Warnings | M013 |
DailyMed RxNorm Mappings#
| RxCUI | RxNorm string | TTY | DailyMed | SPL version |
|---|---|---|---|---|
| 211292 | ANACIN 400 MG / 32 MG Oral Tablet | PSN | 51ab0ee3-3c94-424d-a30a-2d6c14e3d8ff | 9 |
| 198479 | aspirin 400 MG / caffeine 32 MG Oral Tablet | PSN | 51ab0ee3-3c94-424d-a30a-2d6c14e3d8ff | 9 |
| 211292 | aspirin 400 MG / caffeine 32 MG Oral Tablet [Anacin] | SBD | 51ab0ee3-3c94-424d-a30a-2d6c14e3d8ff | 9 |
| 198479 | aspirin 400 MG / caffeine 32 MG Oral Tablet | SCD | 51ab0ee3-3c94-424d-a30a-2d6c14e3d8ff | 9 |
| 211292 | Anacin (ASA 400 MG / caffeine 32 MG) Oral Tablet | SY | 51ab0ee3-3c94-424d-a30a-2d6c14e3d8ff | 9 |
| 198479 | ASA 400 MG / Caffeine 32 MG Oral Tablet | SY | 51ab0ee3-3c94-424d-a30a-2d6c14e3d8ff | 9 |
| 211292 | ASA 400 MG / Caffeine 32 MG Oral Tablet [Anacin] | SY | 51ab0ee3-3c94-424d-a30a-2d6c14e3d8ff | 9 |
Packages#
| Package NDC | 11-digit format | Description | Units | Marketing start | Marketing end | Sample | Exclude flag | Status |
|---|---|---|---|---|---|---|---|---|
| 63736-200-04 | 63736020004 | 1 BLISTER PACK in 1 BOX (63736-200-04) > 4 TABLET in 1 BLISTER PACK | 1 blister pack | 2009-06-25 | 2023-06-30 | No | No | Current |
| 63736-200-30 | 63736020030 | 1 BOTTLE in 1 BOX (63736-200-30) > 30 TABLET in 1 BOTTLE | 1 bottle | 2009-06-25 | 2023-06-30 | No | No | Current |
| 63736-200-50 | 63736020050 | 1 BOTTLE in 1 BOX (63736-200-50) > 50 TABLET in 1 BOTTLE | 1 bottle | 2009-06-25 | 0000-00-00 | No | No | Current |
| 63736-200-90 | 63736020090 | 1 BOTTLE in 1 BOX (63736-200-90) / 100 TABLET in 1 BOTTLE | 1 bottle | 2009-06-25 | 0000-00-00 | No | No | Current |
| 63736-200-91 | 63736020091 | 1 BOTTLE in 1 BOX (63736-200-91) > 130 TABLET in 1 BOTTLE | 1 bottle | 2009-06-25 | 2023-06-30 | No | No | Current |
| 63736-200-92 | 63736020092 | 125 POUCH in 1 BOX (63736-200-92) > 1 TABLET in 1 POUCH | 125 pouch | 2009-06-25 | 0000-00-00 | No | No | Current |
| 63736-200-93 | 63736020093 | 1 BOTTLE in 1 BOX (63736-200-93) / 300 TABLET in 1 BOTTLE | 1 bottle | 2009-06-25 | 0000-00-00 | No | No | Current |
| 63736-200-95 | 63736020095 | 750 POUCH in 1 BOX (63736-200-95) > 1 TABLET in 1 POUCH | 750 pouch | 2009-06-25 | 2023-06-30 | No | No | Current |